JP2004534064A - アルツハイマー病の治療に有用な大環状分子 - Google Patents

アルツハイマー病の治療に有用な大環状分子 Download PDF

Info

Publication number
JP2004534064A
JP2004534064A JP2003503623A JP2003503623A JP2004534064A JP 2004534064 A JP2004534064 A JP 2004534064A JP 2003503623 A JP2003503623 A JP 2003503623A JP 2003503623 A JP2003503623 A JP 2003503623A JP 2004534064 A JP2004534064 A JP 2004534064A
Authority
JP
Japan
Prior art keywords
alkyl
ethyl
optionally substituted
diaza
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003503623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534064A5 (https=
Inventor
プーリー、ション、アール
ベック、ジェイムズ、ピー
イ− テンブリンク、ル−ス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2004534064A publication Critical patent/JP2004534064A/ja
Publication of JP2004534064A5 publication Critical patent/JP2004534064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003503623A 2001-06-12 2002-06-12 アルツハイマー病の治療に有用な大環状分子 Pending JP2004534064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29754601P 2001-06-12 2001-06-12
US33308301P 2001-11-19 2001-11-19
PCT/US2002/019076 WO2002100856A1 (en) 2001-06-12 2002-06-12 Macrocycles useful in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2004534064A true JP2004534064A (ja) 2004-11-11
JP2004534064A5 JP2004534064A5 (https=) 2006-01-05

Family

ID=26970209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503623A Pending JP2004534064A (ja) 2001-06-12 2002-06-12 アルツハイマー病の治療に有用な大環状分子

Country Status (10)

Country Link
US (2) US6969709B2 (https=)
EP (1) EP1404671B1 (https=)
JP (1) JP2004534064A (https=)
AT (1) ATE323084T1 (https=)
BR (1) BR0210392A (https=)
CA (1) CA2450202A1 (https=)
DE (1) DE60210614T2 (https=)
ES (1) ES2261699T3 (https=)
MX (1) MXPA03011466A (https=)
WO (1) WO2002100856A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526913A (ja) * 2005-01-13 2008-07-24 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物
JP2008526912A (ja) * 2005-01-13 2008-07-24 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物および組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214736A (pt) * 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
US7371853B2 (en) 2003-01-07 2008-05-13 Merck & Co., Inc. Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7521420B2 (en) 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
DE602005007245D1 (https=) * 2004-07-28 2008-07-10 Schering Corp
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
WO2007021793A1 (en) * 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
CA2656869A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
JP2009544599A (ja) * 2006-07-20 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物
US7678784B2 (en) 2006-11-20 2010-03-16 Bristol-Myers Squibb Company Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors
US7772221B2 (en) 2007-02-09 2010-08-10 Bristol-Meyers Squibb Company Diaminopropane derived macrocycles as inhibitors of β amyloid production
US20100063013A1 (en) * 2007-03-26 2010-03-11 Renata Oballa Cathepsin cysteine protease inhibitors
US7732434B2 (en) 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
US20160022649A1 (en) * 2013-03-15 2016-01-28 The Board Of Regents Of The University Of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors
EP1192177A1 (en) * 1999-06-15 2002-04-03 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526913A (ja) * 2005-01-13 2008-07-24 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物
JP2008526912A (ja) * 2005-01-13 2008-07-24 ノバルティス アクチエンゲゼルシャフト Ｂａｃｅ阻害剤として有用な大環状化合物および組成物

Also Published As

Publication number Publication date
US6969709B2 (en) 2005-11-29
CA2450202A1 (en) 2002-12-19
ES2261699T3 (es) 2006-11-16
MXPA03011466A (es) 2004-07-01
BR0210392A (pt) 2004-10-13
DE60210614T2 (de) 2007-03-01
US20060040910A1 (en) 2006-02-23
ATE323084T1 (de) 2006-04-15
EP1404671B1 (en) 2006-04-12
US20030236199A1 (en) 2003-12-25
DE60210614D1 (de) 2006-05-24
EP1404671A1 (en) 2004-04-07
US7442691B2 (en) 2008-10-28
WO2002100856A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
US7067507B2 (en) Macrocycles useful in the treatment of Alzheimer's disease
US7358264B2 (en) Statine derivatives for the treatment of Alzheimer's disease
US20060100196A1 (en) Substituted amines for the treatment of alzheimer's disease
JP2004502664A (ja) アルツハイマー病処置用化合物
JP2004534064A (ja) アルツハイマー病の治療に有用な大環状分子
JP2005500319A (ja) アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
JP2005534614A (ja) アルツハイマー病治療のための置換アミノカルボキサミド
KR20050049485A (ko) 1,3-디아미노-2-히드록시프로판 전구약물 유도체
JP2005511735A (ja) 置換ヒドロキシエチルアミン
JP2006524255A (ja) ベンズアミド２−ヒドロキシ−３−ジアミノアルカン
JP2006524258A (ja) フェナシル２−ヒドロキシ−３−ジアミノアルカン
JP2005504022A (ja) アルツハイマー病治療のためのジアミンジオール
US20090291970A1 (en) Substituted Aminoethers for the Treatment of Alzheimer's Disease
JP2004532894A (ja) アルツハイマー病を治療するためのアミンジオール
WO2004058686A1 (en) Hydroxypropyl amides for the treatment of alzheimer’s disease
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
JP2004534771A (ja) アザヒドロキシル化エチルアミン化合物
JP2005536448A (ja) アミン１，２−及び１，３−ジオール化合物、及びアルツハイマー病を治療するためのその使用
JP2006501282A (ja) アルツハイマー病治療のための化合物
JP2007509988A (ja) アルツハイマー病治療のためのヒドロキシプロピルアミド
MXPA03011442A (es) Macrociclos utiles en tratamiento de enfermedad de alzheimer.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090701